is glp 1 safe for kidney disease GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic Chronic Kidney Disease: Stages, Treatments – GLP-1 drugs may extend life,

Key Features of IGF-1 LR3: Extended Half-Life : Modified with an amino acid substitution (arginine in position 3) and a longer chain, allowing for longer activity and reduced binding to IGF-binding proteins (IGFBPs)

PubMed Duzel, A., Vlainic, J., Antunovic, M., Malekinusic, D., Vrdoljak, B., Samara, M., Gojkovic, S., Krezic, I., Vidovic, T., Bilic, Z., Sjekavica, I., Djuzel, A.R., Knezevic, M., Sever, A.Z., Lojo, N., Kokot, A., Sever, M., Drmic, D., Seiwerth, S., Sikiric, P

The secondary endpoint was alleviation of hepatic encephalopathy and improved results in the NCT-B

How will benefit be measured before deciding to repeat treatment